2021-05-13T15:01:07-05:00 2020-06-30 135565207 KPMG LLP 300 NORTH GREENE STREET SUITE 400 GREENSBORO NC 27401 990 2019-07-01 730580274 Oklahoma Medical Research Foundation OKLA 4052717421 825 NE 13th Street Oklahoma City OK 73104 Tim Hassen VP and Chief Financial Officer 2021-05-13 true SHAWN HUTCHINSON P01048557 3362753394 2019 2022-09-23 18:48:47Z Tim Hassen VP and CFO 825 NE 13th Street Oklahoma City OK 73104 226924420 false X www.omrf.org X 1946 OK Oklahoma Medical Research Foundation (OMRF) is dedicated to developing a better understanding of and more effective treatments for human disease. 67 67 595 67 6337 4703 60132921 60164768 24773802 25257648 5386846 4241526 6231501 5464755 96525070 95128697 0 0 38524021 39778322 0 1923654 51008364 48830203 89532385 88608525 6992685 6520172 415080137 416096679 55619740 51737436 359460397 364359243 X OMRF is dedicated to developing a better understanding of more effective treatments for human disease. false false 34190114 0 25257648 Arthritis and Clinical Immunology/Clinical Operations - When the pandemic struck, physicians and scientists in this program pivoted to assist in the fight against Covid-19. Rheumatologists tapped their expertise in autoimmune disease to offer insights on treating Covid-19 and prepared a comprehensive review of therapeutic and vaccine strategies. Others repurposed research equipment to create a diagnostic testing lab that helped ease testing shortages across the state. And in the largest, most comprehensive effort, a team of scientists who'd been studying anthrax received a federal grant to investigate why some people become extremely sick when infected with the virus, while others do not. 6798603 0 0 Cardiovascular Biology Research Program - A 2020 discovery in this program could pave the way for therapies to reverse vision loss common in premature infants and adults. In a study appearing in the Proceedings of the National Academy of Sciences, OMRF scientists identified a compound that could give birth to therapies for a host of eye diseases that include retinopathy of prematurity and diabetic retinopathy. "Potentially, even patients with advanced disease progression could see their fortunes turned around," said Dr. Courtney Griffin, the senior author of the study. "This could be a major advance in treatment for vision loss in patients of all ages." 5548507 0 0 Aging and Metabolism Research Program - Scientists in this program study a host of different disease processes, but their work unites in a common theme: extending the health span of our aging population. In 2020, they progressed toward this goal in a variety of ways. One scientist launched a clinical trial of the diabetes drug metformin to study its effects on the aging process. Another began a collaborative study focused on countering osteoarthritis through the use of anti-inflammatory treatments and exercise therapy. The year ended with OMRF teaming with a pair of Oklahoma institutions to secure designation and funding by the National Institutes of Health as a Nathan Shock Center of Excellence in the Basic Biology of Aging, one of only eight in the U.S. 35646576 0 3887635 Other program services include departments such as Cell Cycle and Cancer Biology, Genes and Human Disease, Genetic Models of Disease and other scientific and research support services. 35646576 3887635 82183800 true true false true false false false false true true true false true true true true true false false true false false false true false false false false true true false false false false false false false false true true true false false false true false false false false true 148 0 true 595 true true true false false false true true true true false false false true true false false false X 67 67 true false false false false false false true true false false true true true true true true true true false OK X X Tim Hassen VP and Chief Financial Officer 4052717421 825 NE 13th Street Oklahoma City OK 73104 Albers Leigh Ann Board Member 1.0 X 0 0 0 Anoatubby Bill Board Member 1.0 X 0 0 0 Bell Sharon Board Member 1.0 X 0 0 0 Benbrook Bruce Board Member 1.0 X 0 0 0 Benham Lance Board Member 1.0 X 0 0 0 Boghetich JII Board Member 1.0 X 0 0 0 Braught Barbara Board Member 1.0 X 0 0 0 Brown Randy Board Member 1.0 X 0 0 0 Burgess Ellen Board Member 1.0 X 0 0 0 Carolina Mike Board Member 1.0 X 0 0 0 Cason Len Board Member 1.0 X 0 0 0 Cawley Michael Board Member 1.0 X 0 0 0 Champlin Hiram Board Member 1.0 X 0 0 0 Collins Mark Board Member 1.0 X 0 0 0 Drake Ramsey Board Member 1.0 X 0 0 0 Duncan Walt Board Member 1.0 X 0 0 0 Eagan Claire Board Member 1.0 X 0 0 0 Edwards Carl Board Member 1.0 X 0 0 0 Everest Christy Board Member 1.0 X 0 0 0 Everest Tricia Board Member 1.0 X 0 0 0 Felton Ann Board Member 1.0 X 0 0 0 Fergeson Ken Board Member 1.0 X 0 0 0 Funke Mark Board Member 1.0 X 0 0 0 Gamble Gerald Board Member 1.0 X 0 0 0 Griffin John Board Member 1.0 X 0 0 0 Groendyke Virginia Board Member 1.0 X 0 0 0 Haglund Jacqui Board Member 1.0 X 0 0 0 Hall Brooks Board Member 1.0 X 0 0 0 Hargis Burns Board Member 1.0 X 0 0 0 Hatfield Judy Board Member 1.0 X 0 0 0 Hawley Bill Board Member 1.0 X 0 0 0 Henry Kim Board Member 1.0 X 0 0 0 Hogan Randy Board Member 1.0 X 0 0 0 Holmes Jerome Board Member 1.0 X 0 0 0 Hudson Cliff Board Member 1.0 X 0 0 0 Irani Ronnie Board Member 1.0 X 0 0 0 Jameson Brett Board Member 1.0 X 0 0 0 Johnstone Bill Board Member 1.0 X 0 0 0 Kelly Michael Board Member 1.0 X 0 0 0 Kern Terence Board Member 1.0 X 0 0 0 Kerr Lou Board Member 1.0 X 0 0 0 Levy Harrison Board Member 1.0 X 0 0 0 Little Dan Board Member 1.0 X 0 0 0 Loughridge Bill Board Member 1.0 X 0 0 0 Mahaney Mindy Board Member 1.0 X 0 0 0 McCarty Jack Board Member 1.0 X 0 0 0 Morris Jim Board Member 1.0 X 0 0 0 Nichols Larry Board Member 1.0 X 0 0 0 Parry Richard Board Member 1.0 X 0 0 0 Patten Rebecca Board Member 1.0 X 0 0 0 Payne Bond Board Member 1.0 X 0 0 0 Pollard Barry Board Member 1.0 X 0 0 0 Rainbolt David Board Member 1.0 X 0 0 0 Replogle Dee Board Member 1.0 X 0 0 0 Rooney Pat Board Member 1.0 X 0 0 0 Ross Bob Board Member 1.0 X 0 0 0 Samis Mike Board Member 1.0 X 0 0 0 Saxon John Board Member 1.0 X 0 0 0 Schulte Paul Board Member 1.0 X 0 0 0 Stough Phyllis Board Member 1.0 X 0 0 0 Swimmer Ross Board Member 1.0 X 0 0 0 Switzer Becky Board Member 1.0 X 0 0 0 Taylor Steven Board Member 1.0 X 0 0 0 Thorpe Betsy Board Member 1.0 X 0 0 0 Walton Greg Board Member 1.0 X 0 0 0 Williams G Rainey Jr Board Member 1.0 X 0 0 0 Yauk Sarah Board Member 1.0 X 0 0 0 Cohen Adam Sr VP and General Counsel 50.0 X 253724 0 51805 Courtney Greenwood VP of Human Resources 50.0 X 167263 0 39611 Day Lisa VP of Government Affairs 50.0 X 134614 0 21842 Hassen Tim VP and CFO 50.0 X 244000 0 59525 James Judith VP of Clinical Affairs and Program Chair 50.0 X 457972 0 100851 McEver Rodger MD VP of Research and Member 50.0 X 329292 0 42434 Prescott Stephen MD President and CEO 50.0 X 997371 0 43274 Voss Penny VP of Development 50.0 X 218957 0 59960 Gaffney Patrick MD Program Chair, Genes and Human Disease 50.0 X 301483 0 58317 Pardo Gabriel MD Associate Member, Arthritis and Clinical Immunoid 50.0 X 336269 0 48198 Xia Lijun MD Program Chair and Cardiovascular Biology 50.0 X 281989 0 74902 Jennifer Criley DVM Director of Comparative Medicine & Attending Veterinarian 50.0 X 207212 0 25906 Joan Merrill MD Member, Arthritis and Clinical Immunology 50.0 X 251229 0 28192 Lupu Florea PhD Member, Cardiovascular Biology 50.0 X 276474 0 37882 Nath Swapan PhD Member, Arthritis and Clinical Immunology 50.0 X 278109 0 49945 Rezaie Alireza PhD Member, Cardiovascular Biology 50.0 X 256774 0 40485 Morgan Chip Executive VP & Chief Operating Officer 50.0 X 248776 0 41317 Nair Manu VP of Technology Ventures 50.0 X 234223 0 43919 5475731 0 868365 65 true true false Infusion Management LLC 11233 Shadow Creek Pwky Suite 303 Pearland TX 77584 Medical Billing Services 20827927 Aramark 24863 Network Pl Chicago IL 606731248 HouseKeeping Services 502450 Mcallister & Quinn LLC 1030 15th St NW Suite 590 W Washington DC 20005 Grant application review services 125000 Grant Thornton LLP 211 N Robinson Suite 1200 Oklahoma City OK 73102 Audit services 105400 4 106040 692760 30889184 28476784 319747 60164768 Clinic Revenue 621990 25257648 25257648 0 0 0 0 25257648 1973127 -4503 1977630 98711 98711 2728976 1761708 967268 456880 456880 0 456880 456880 133328549 493874 130969326 683409 2359223 -189535 2169688 10840 2158848 83188 692760 142988 -59800 -59800 Laboratory Income 621500 2125928 2125928 Cafe Income 722514 212771 212771 0 0 0 0 2338699 95128697 29145284 6337 5812308 3421450 2692073 510420 218957 27018022 24824753 1165424 1027845 2240169 2025080 123332 91757 5099114 4405626 519621 173867 1999567 1807579 110086 81902 116933 83719 33214 123500 123500 62265 62265 1185667 1185667 0 0 533424 330072 69715 133637 946164 785312 138197 22655 3820951 3055638 765313 428027 380601 37013 10413 90851 90260 591 911620 898155 13465 8071357 7709871 361486 299578 214485 85093 Lab supplies 5633348 5633348 Trainee costs 1127936 1127936 Inhouse 990931 963392 19758 7781 Subcontracts 22448636 22448636 2039015 1521597 362578 154840 88608525 82183800 4501071 1923654 3640 3640 20330349 29057583 8527729 9295029 5264915 6175900 0 0 0 0 52500 0 12735 12243 524743 465916 239174213 144379032 98266168 94795181 121232724 113247515 15002777 21446654 0 0 145861857 141597018 415080137 416096679 13066821 10516507 0 1060576 2192510 34810000 31965000 0 0 0 0 0 0 0 0 6682343 7063419 55619740 51737436 X 120292368 124900551 239168029 239458692 359460397 364359243 415080137 416096679 X 6520172 1719448 0 0 0 -3340774 X false true X true true true X 55448766 58391949 58406493 60132921 60164768 292544897 0 0 0 0 0 0 0 0 0 0 0 0 55448766 58391949 58406493 60132921 60164768 292544897 51427797 241117101 6651582 6182195 8549189 13563861 3495987 38442814 0 0 5304 81073 5337 91714 287716 732460 334103 347212 295959 1997450 333076875 109181360 0.7239 0.7134 X Schedule A, Part II, Line 10 Schedule A, Part II, Line 10 Other income includes cafeteria sales as well as fundraising income that was not included in contributions. Schedule A, Part II, Line 10 Other Income DESCRIPTION - , COLUMN A - 287716.0, COLUMN B - 732460.0, COLUMN C - 334103.0, COLUMN D - 347212.0, COLUMN E - 295959.0, COLUMN F - 1997450.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 385970 false false 385970 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY The Foundation's lobbying activities entail monitoring proposed legislation and educating legislators and their staffs about the Foundation, medical research and the impact of proposed legislation on medical research and the Foundation. 115938978 26722 4715393 0 4400000 0 116281093 97512842 16719850 5906286 0 4200000 0 115938978 91545136 75342 9892364 0 4000000 0 97512842 82018035 246125 13280976 0 4000000 0 91545136 86604791 389217 -1175973 0 3800000 0 82018035 0.2064 0.4754 0.3182 true false 4080847 4080847 185261984 106920932 78341052 49764563 37458100 12306463 66819 66819 94795181 Other securites 21446654 F 21446654 Funds held in trust by others 134393763 Wills and Bequests 2451207 Cash Surrender Value of Life Insurance 4433698 Debt Issue Costs 168382 Deposits 42260 Accrued Interest Receivable 59627 Assets Held for Sale 47970 Minerals 111 141597018 Postretirement Benefits and Deferred Comp 6952545 Split Interest Agreements 110874 7063419 X 93507371 1719448 -3340774 -1621326 95128697 0 0 95128697 88608525 0 0 88608525 0 0 88608525 Schedule D, Part V, Line 4 Intended uses of endowment funds The Foundation's endowment consists of individual funds established to provide the Foundation with funding in perpetuity. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote The Foundation is a public foundation exempt from federal income tax under section 501(c)(3) of the internal revenue code except for amounts relating to unrelated business income. There were no known material unrelated business income taxes incurred in 2020 and accordingly, no provision for income taxes has been made in these financial statements. Management has reviewed the Foundation's tax position and concluded that there are no uncertain tax positions that require accrual in the consolidated financial statements or disclosure in the footnotes to be in compliance with authoritative literature. Generally, the Foundation is no longer subject to income tax examination by federal, state or local tax authorities for years prior to 2017. The statute of limitations will remain open for both federal and state purposes for any returns not filed. Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990 CHANGES IN FAIR VALUE OF FUNDS HELD IN TRUST - -3784859 PENSION RELATED CHANGES OTHER THAN NET PERIODIC PENSION COSTS - 444085 East Asia and the Pacific 0 6 Conference Travel 7087 Europe (Including Iceland and Greenland) 0 26 Conference Travel 21328 Europe (Including Iceland and Greenland) 0 12 Program Services Student Program 17880 North America (Canada & Mexico only) 0 4 Conference Travel 3944 South Asia 0 1 Program Services Intellectual Property/Research Collaboration 3179 South Asia 0 1 Conference Travel 6157 Central America and the Caribbean 0 0 Investments 5876654 North America (Canada & Mexico only) 0 0 Investments 697193 0 50 0 0 0 50 6633422 0 6633422 true false false false true false Schedule F, Part I, Line 3 Program service activity in all regions includes scientists attending and/or speaking at scientific conferences and collaborations. OMRF does not maintain ongoing operations in foreign jurisdictions, however the Foundation's scientists do travel to various scientific conferences in other countries to share in scientific discoveries, as well as to learn from other scientists across the world. 241 EVENT 508072 435994 72078 2515 29023 18354 30771 28796 MS DINNER 267876 256766 11110 2078 15925 1702 13824 0 775948 692760 83188 2515 31101 34279 32473 42620 142988 -59800 X X true true X X X X X false true false false false false false true false Prescott Stephen MD President and CEO 838777 0 111600 0 46994 0 30785 0 12489 0 1040645 0 0 0 Cohen Adam Sr VP and General Counsel 207252 0 0 0 46472 0 41236 0 10569 0 305529 0 0 0 Voss Penny VP of Development 198395 0 0 0 20562 0 45726 0 14234 0 278917 0 0 0 Hassen Tim VP and CFO 225583 0 425 0 17992 0 40677 0 18848 0 303525 0 0 0 Day Lisa VP of Government Affairs 128057 0 0 0 6557 0 11548 0 10294 0 156456 0 0 0 Courtney Greenwood VP of Human Resources 162068 0 125 0 5070 0 20726 0 18885 0 206874 0 0 0 James Judith VP of Clinical Affairs and Program Chair 412510 0 175 0 45287 0 89837 0 11014 0 558823 0 0 0 McEver Rodger MD VP of Research and Member 281518 0 0 0 47774 0 30545 0 11889 0 371726 0 0 0 Pardo Gabriel MD Associate Member, Arthritis and Clinical Immunoid 333577 0 0 0 2692 0 30100 0 18098 0 384467 0 0 0 Gaffney Patrick MD Program Chair, Genes and Human Disease 286741 0 0 0 14742 0 40219 0 18098 0 359800 0 0 0 Xia Lijun MD Program Chair and Cardiovascular Biology 256465 0 0 0 25524 0 56804 0 18098 0 356891 0 0 0 Nath Swapan PhD Member, Arthritis and Clinical Immunology 253797 0 0 0 24312 0 31127 0 18818 0 328054 0 0 0 Lupu Florea PhD Member, Cardiovascular Biology 243049 0 0 0 33425 0 30785 0 7097 0 314356 0 0 0 Rezaie Alireza PhD Member, Cardiovascular Biology 213299 0 0 0 43475 0 27869 0 12616 0 297259 0 0 0 Joan Merrill MD Member, Arthritis and Clinical Immunology 229255 0 0 0 21974 0 26931 0 1261 0 279421 0 0 0 Jennifer Criley DVM Director of Comparative Medicine & Attending Veterinarian 206812 0 0 0 400 0 15000 0 10906 0 233118 0 0 0 Morgan Chip Executive VP & Chief Operating Officer 221114 0 75 0 27587 0 26896 0 14421 0 290093 0 0 0 Nair Manu VP of Technology Ventures 213558 0 75 0 20590 0 25753 0 18166 0 278142 0 0 0 Schedule J, Part I, Line 3 Compensation for the CEO is determined by leadership of the board of directors based on comparability data from widely accepted peer benchmarking surveys that are segmented by region and size of entity. Schedule J, Part I, Line 1a First-class or charter travel First class travel is allowed for the CEO to allow him to accomplish work related to tasks while traveling. Schedule J, Part I, Line 1a Travel for companions Travel for companions is allowed in certain limited circumstances where the companion's presence has a benefit to the Foundation but does not qualify as a business expense under IRS rules. In those limited cases the companion's travel expenses are treated as taxable compensation. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan The Board of the Foundation periodically uses non-qualified retirement plans as a retention tool. The amount reported is the amount vested in the 457(f) plan. The remaining amount of the plan is not vested and is subject to substantial risk of forfeiture. Schedule J, Part I, Line 7 Non-fixed payments The CEO receives an annual bonus that is determined by leadership of the board of directors based on performance. The bonus is considered as a portion of total compensation and is subject to the review process previously described. A Oklahoma Industries Authority Revenue Bonds (OMRF Project) Series 2010 736194355 000000000 2010-05-26 12185000 Refunding of Prior year 2001 bond false false false B Oklahoma Industries Authority Revenue Bonds (OMRF Project) Series 2016 736194355 000000000 2016-07-13 29535000 Refunding of prior year 2008 bond false false false A 0 0 12185000 96500 0 11946495 142005 0 0 0 0 0 2010 true true true true B 9755000 0 29535000 2953564 0 26315325 266175 0 0 0 0 0 2016 false true true true A false false false true true 0.0 0.0 0.0 false false true B false false false true true 0.0 0.0 0.0 false false true A true false false false false true B false true false false false false false false true A true B true Schedule K, Part I 05/26/2010 12185000 Oklahoma Industries Authority In May 2010, the Foundation issued 12,185,000 of Oklahoma Industrial Authorities ("OIA") Series 2010 Revenue Bonds (the "Series 2010 Bonds") dated May 1, 2010. The proceeds from the Series 2010 Bonds were used to retire the OIA 2001 Series Bonds on February 1, 2011. The Series 2010 Bonds mature February 1, 2021 and bear interest at the stated rate of 4.375% per annum. Interest payments began July 1, 2010 and are due on August 1st and February 1st of each year through 2021, at which time the principal will be due in its entirety. The Series 2010 bonds were issued with no premium or discount. The Series 2010 Bond agreements also require maintenance of a reserve fund which is included in investments in the accompanying statement of financial position. This amount was approximately $96,500 as of June 30, 2020. Schedule K, Part I 07/13/2016 29535000 Oklahoma Industries Authority In July 2016, the Foundation entered into advanced refinancing of the Series 2008 bonds. The Foundation issued $43,955,000 of OIA Series 2008 Revenue Bonds (the "Series 2008 Bonds") dated July 1, 2008; the proceeds from this bond were used to construct and equip a new research facility. The Series 2008 Bonds were defeased when the Foundation issued $29,535,000 of OIA Series 2016 Revenue Bonds (the "Series 2016 Bonds") dated July 13, 2016. The Series 2016 bonds mature on July 1, 2026 and bear interest at the stated rate of 1.81% per annum. Payments of principal and interest began January 1, 2017 and are due January 1st and July 1st of each year. The Series 2016 Bond agreements also require maintenance of a reserve fund which is included in investments in the accompanying statement of financial position. This amount was $2,953,500 as of June 30, 2020. Michelle Morgan Related to Officer 45032 Employment false X 19 861639 Market value 0 false true false Form 990, Part III, Line 4d Description of other program services (Expenses $ 35,646,576 including grants of $ 0)(Revenue $ 3,887,635) Other program services include departments such as Cell Cycle and Cancer Biology, Genes and Human Disease, Genetic Models of Disease and other scientific and research support services. Form 990, Part VI, Line 1a Delegate broad authority to a committee The Foundation's Board of Directors has delegated all of its powers to the Foundation's Executive Committee, except as follows: establish the overall policies and direction of the Foundation, appoint the members of the Executive Committee, elect and remove the Chair of the Board of Directors, amend the Bylaws and the Certificate of Incorporation of the Foundation, and appoint special committees to the Board of Directors. The Board of Directors may at any time amend or revoke this delegation of powers. Form 990, Part VI, Line 11b Review of form 990 by governing body The Form 990 is prepared by the Foundation, internally reviewed by the CFO. The Form 990-T is externally reviewed by the tax department of a public accounting firm. A summary of the Form 990 is presented for review to the Executive Committee. Subsequent to that review, the Form 990 with all supplemental schedules is made available to all members of the board of directors for review and comment prior to filing. Form 990, Part VI, Line 12c Conflict of interest policy Each director, officer and key employee is annually provided with a copy of the Foundation's conflict of interest policy. Each of these individuals is annually provided with a questionnaire regarding potential conflicts and required to disclose any potential conflict that he or she might have. In addition, each of these individuals must annually sign a statement affirming that he or she has; received a copy of the conflicts of interest policy, read and understood the policy and agrees to comply with the policy. Once the Foundation has collected annual disclosure statements from all directors, officer and key employees, the Foundation's Governance Committee reviews such information to identify situations in which a potential conflict exists and is material. If a potential material conflict is identified, the committee analyzes whether the contemplated transaction may be authorized as just, fair, and reasonable to the Foundation. The Governance Committee then makes a recommendation to the Foundations' Executive Committee regarding the management of all potential conflicts it has identified. The final decision as to the approval and , where applicable, management of all such potential conflicts rests in the sole discretion of the Executive Committee, which makes such decisions based upon the welfare of the Foundation and the advancement of its purpose. The recommendations of the Governance Committee and decisions of the Executive Committee are documented in the respective minutes of these Committees' regular meetings. Form 990, Part VI, Line 15a Process to establish compensation of top management official Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Line 15b Process to establish compensation of other employees Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Line 18 How forms are made available to the public The Foundation's Form 990 for the last three years are publicly available on the Foundation's website, as well as on Guidestar and other nonprofit databases. Form 1023, 990, and 990-T are provided upon request. Form 990, Part VI, Line 19 Required documents available to the public The Foundation's governing documents, conflict of interest policy, and financial statements are provided upon request and are publicly available on the Foundation's website. Form 990, Part XI, Line 9 Other changes in net assets or fund balances CHANGES IN FAIR VALUE OF FUNDS HELD IN TRUST - -3784859; PENSION RELATED CHANGES OTHER THAN NET PERIODIC PENSION COSTS - 444085; Form 990, Part VI Section A, Line 2 The Foundation currently has 67 directors, many of whom are business leaders and members of prominent families in the State of Oklahoma. The Foundation believes there are multiple business relationships between and among board members and families of Board members, but the Foundation review of signed conflict of interest disclosures from all board members and of the Foundation's ledger accounts indicated there are no such relationships that would impair the fiduciary duties of any director to the Foundation. Culbertson Plaza LLC 825 NE 13th Street Oklahoma City OK 73104 842527142 Manage real property known as the Culbertson Plaza Shopping Center OK 77108 1511791 Oklahoma Medical Research Foundation